Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals CRISPR Collaboration by Year
CRISPR Collaboration — Pre-commercialization SG&A expense (historical, $M) ($M)
Vertex Pharmaceuticals CRISPR Collaboration: $32M in FY2023, up 32.2% from a year earlier. No newer figure appears in the documents we track.
Where the FY2023 figure comes from
Source: Form 10-K (filed 2026-02-13) ↗
Reported in Form 10-Q / 10-K Note (Collaborative Arrangements — CRISPR Therapeutics).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | CRISPR Collaboration — Pre-commercialization SG&A expense (historical, $M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 32 | +32.2% | Form 10-K (filed 2026-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 24.2 | +16.3% | Form 10-K (filed 2025-02-13) ↗ |
| FY2021 | Dec 31, 2021 | 20.8 | – | Form 10-K (filed 2024-02-15) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals CRISPR Collaboration ($M), annual FY2021–FY2023 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/crispr-sga
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.